Twist Bioscience (NASDAQ:TWST) CEO Sells 113,318 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 113,318 shares of Twist Bioscience stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the sale, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This trade represents a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Trading Up 1.7%

Shares of TWST traded up $2.09 during trading hours on Wednesday, hitting $125.21. 1,605,568 shares of the stock traded hands, compared to its average volume of 1,523,305. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $125.66. The firm has a market capitalization of $7.85 billion, a PE ratio of -56.40 and a beta of 2.14. The business has a fifty day moving average of $91.49 and a 200-day moving average of $65.64.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 EPS. Analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Robert W. Baird lifted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Barclays increased their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a research note on Monday, June 15th. Canaccord Genuity Group lifted their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Institutional Trading of Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in Twist Bioscience during the 3rd quarter worth $28,000. Western Wealth Management LLC acquired a new position in Twist Bioscience in the first quarter valued at about $31,000. Strs Ohio acquired a new position in Twist Bioscience in the first quarter valued at about $33,000. Strategic Advocates LLC increased its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.